Amundi Purchases 1,614,355 Shares of Gilead Sciences, Inc. $GILD

Amundi lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 18.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,467,411 shares of the biopharmaceutical company’s stock after acquiring an additional 1,614,355 shares during the period. Amundi owned 0.84% of Gilead Sciences worth $1,167,221,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after purchasing an additional 727,515 shares during the last quarter. Norges Bank bought a new stake in Gilead Sciences in the second quarter worth about $2,150,268,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after buying an additional 1,520,809 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GILD. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. BMO Capital Markets set a $135.00 price objective on Gilead Sciences in a report on Tuesday, November 25th. Scotiabank assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. Truist Financial assumed coverage on shares of Gilead Sciences in a report on Monday, November 24th. They issued a “buy” rating and a $140.00 target price on the stock. Finally, Morgan Stanley upped their price target on Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $130.65.

Insider Transactions at Gilead Sciences

In related news, Director Kelly A. Kramer sold 2,806 shares of the stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $127.11, for a total transaction of $356,670.66. Following the sale, the director owned 1,339 shares in the company, valued at approximately $170,200.29. This represents a 67.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 135,757 shares of company stock worth $16,616,127. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 1.9%

Gilead Sciences stock opened at $122.62 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock has a market cap of $152.13 billion, a PE ratio of 19.01, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The stock has a fifty day moving average of $120.76 and a 200 day moving average of $115.14. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the company earned $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.